Indrayani Biotech Q1 FY27 Consolidated Revenue Rs. 3,770.55 Lakhs, Profit Rs. 58.88 Lakhs
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 07 Oct 2026, 05:58 PM IST · BSE ID: e13b47dd-cac9-4ece-ad3a-2d714f036c38
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its first quarter financial results for the year ending June 2026 and reorganized its board committees.
🤖 AI Summary
- Indrayani Biotech Board approved Q1 FY27 unaudited standalone and consolidated financial results on October 07, 2026.
- Consolidated revenue from operations for the quarter ended June 30, 2026, was Rs. 3,770.55 Lakhs.
- Consolidated profit before tax for the quarter ended June 30, 2026, was Rs. 58.88 Lakhs.
- The Board reconstituted the Audit, Stakeholder Relationship, and Rights Issue Committees.
- Statutory auditors provided an unmodified opinion on both standalone and consolidated financial results.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from Operations (Q1 FY27)
3,770.55 Lakhs
Consolidated Profit Before Tax (Q1 FY27)
58.88 Lakhs
Standalone Revenue from Operations (Q1 FY27)
415.34 Lakhs
Standalone Profit Before Tax (Q1 FY27)
19.38 Lakhs
Consolidated Revenue from Operations (Q1 FY26)
2,910.37 Lakhs
Standalone Revenue from Operations (Q1 FY26)
668.57 Lakhs
🏢 How This Affects the Company
The company reported consolidated revenue from operations of Rs. 3,770.55 Lakhs for Q1 FY27 and a consolidated profit before tax of Rs. 58.88 Lakhs.
The reconstitution of the Audit, Stakeholder Relationship, and Rights Issue Committees affects corporate governance and oversight functions within the company.
The unmodified opinion from statutory auditors on the financial results indicates no significant accounting discrepancies were found during the review.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance and the composition of its key Board committees, which influence governance and strategy.
🔍
Management Signal
The reconstitution of Board committees suggests management's focus on corporate governance and operational oversight for future strategic initiatives, including a potential Rights Issue.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Next quarterly results — observe revenue and profit trends across standalone and consolidated entities.
Rights Issue details — monitor for further announcements on the Rights Issue mentioned via committee.
Annual General Meeting — check for any further governance or strategic updates.
MEDIUM RISK
Mixed financial performance between standalone and consolidated figures, requiring further observation of trends.
💡 Investor Takeaway
Indrayani Biotech's Q1 FY27 consolidated revenue from operations reached Rs. 3,770.55 Lakhs, with consolidated profit before tax at Rs. 58.88 Lakhs. Standalone revenue declined to Rs. 415.34 Lakhs for the quarter. The Board also reconstituted its Audit, Stakeholder Relationship, and Rights Issue Committees.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated revenue from operations for Q1 FY27 increased to Rs. 3,770.55 Lakhs compared to Rs. 2,910.37 Lakhs in Q1 FY26.
- Statutory auditors provided an unmodified opinion on the unaudited standalone and consolidated financial results.
⚠️ Concerns
- Standalone revenue from operations for Q1 FY27 decreased to Rs. 415.34 Lakhs compared to Rs. 668.57 Lakhs in Q1 FY26.
- Standalone profit before tax for Q1 FY27 was Rs. 19.38 Lakhs, a slight increase from Rs. 17.03 Lakhs in Q1 FY26.
📅 Company Track Record
A previous filing on October 07, 2026, for the same period (Q1 FY27) noted Indrayani Biotech's consolidated revenue was up 29.55% YoY to Rs. 3,770.55 Lakhs, consistent with the current filing.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were Indrayani Biotech's consolidated revenues for Q1 FY27?
Indrayani Biotech reported consolidated revenue from operations of Rs. 3,770.55 Lakhs for the quarter ended June 30, 2026.
What was Indrayani Biotech's consolidated profit before tax for Q1 FY27?
The consolidated profit before tax for Indrayani Biotech for the quarter ended June 30, 2026, was Rs. 58.88 Lakhs.
What were Indrayani Biotech's standalone revenues for Q1 FY27?
Indrayani Biotech's standalone revenue from operations for the quarter ended June 30, 2026, was Rs. 415.34 Lakhs.
Which committees of Indrayani Biotech's Board were reconstituted?
The Audit Committee, Stakeholder Relationship Committee, and Rights Issue Committee of Indrayani Biotech's Board were reconstituted with effect from October 07, 2026.
What was the auditor's opinion on Indrayani Biotech's Q1 FY27 financial results?
The statutory auditors provided an unmodified opinion on the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.